Katherine Van Loon, MD, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.
Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.
Van Loon says that oncologists need further research into how often and for how long patients with gastrointestinal cancers should be monitored. She adds that current guidelines state that patients should be followed up on for approximately five years, though recurrences have happened as far out as 10 years.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More